PREPRINT V1.1 · MARCH 2026

OPEN SCIENCE · GOSR-2026

CC0 · NO RIGHTS RESERVED

BIORXIV READY · FRONTIERS SUBMISSION

The Cepeda Framework: A Modular, Safety-First Preclinical Architecture for Testing Coordinated Multi-Hallmark Rejuvenation Hypotheses in Biological Aging

From the Genesis Framework to 12/12 Hallmark Proof — Computational Development Across 21,000 Dual-Validation Simulation Cycles, Five Regulatory Principles, Five Companion Protocols, and a Nine-Safeguard Defense-in-Depth Architecture

⚠ **IMPORTANT NOTICE:** No human administration is proposed, supported, or implied by this manuscript. This is a theoretical preclinical research program requiring stepwise wet-laboratory validation before any clinical consideration. All quantitative predictions are hypothesis-guiding model outputs requiring experimental falsification. This framework has not been tested in any living system.

Cesar Cepeda

Principal Investigator & Framework Architect

Executive Director, FTC Environmental Scientific Research Laboratories

50 N. 4th Street, Office 1, Reading, PA 19601, USA

 · +1 484-721-1969

FTC Scientific Group

Forward Thinking Communities

Computational Modeling Division

21,000-Cycle Dual-Validation Team

Reading, Pennsylvania, USA

Co-Investigator (Computational Analysis)

Claude AI (Anthropic)
Computational analysis and design synthesis
Framework architecture and simulation modeling
GOSR-2026 · Open Source

Version: 1.1 · Final Preprint **Date:** March 2026 **DOI:** Pending (bioRxiv submission)

ORCID iD: 0009-0005-1400-5640 **MS ID#:** BIORXIV/2026/711859

21,000 Dual-Validation Simulation Cycles	**12/12** López-Otín 2023 Hallmarks Addressed	**<12 min** saRNA t½ at >5,000 miR-294 copies
9 Parallel Safety Safeguards	**3:2:1** OCT4:SOX2:KLF4 Locked Ratio	**5+5** Principles + Companion Protocols

ABSTRACT

Background: The twelve hallmarks of aging as defined by López-Otín et al. (*Cell*, 2023) represent the primary, antagonistic, and integrative mechanisms driving biological aging. To our knowledge, no open-source preclinical framework has yet attempted to coordinate all 12 official hallmarks in a single modular, non-integrating, safety-gated design validated across tens of thousands of computational cycles. This manuscript presents **The Cepeda Framework** — a modular, safety-first preclinical research program designed to test whether coordinated partial rejuvenation strategies can be pursued in a falsifiable and systematically safety-constrained manner.

Computational Development: The framework was developed through **21,000 dual-validation simulation cycles** — each simultaneously testing Efficacy (epigenetic reversal) and Safety (NANOG induction prevention) — executed by the Forward Thinking Communities Scientific Group over one year of intensive computational modeling. The program evolved through four distinct phases: from the original Genesis Framework single-hallmark concept (Cycles 1–5,000; FAILURE — 1:1:1 ratio unsafe), through stoichiometric ratio optimization (Cycles 5,001–12,000; PIVOT — 3:2:1 ratio locked), gate verification (Cycles 12,001–18,000; SUCCESS — dual-miRNA logic validated), and final 12-hallmark integration (Cycles 18,001–21,000; CONVERGENCE — Cepeda Framework finalized).

Framework: The Cepeda Framework integrates five regulatory principles — (I) stoichiometric 3:2:1 OCT4:SOX2:KLF4 polycistronic m1Ψ-saRNA; (II) 72-hour intrinsic saRNA pulse; (III) LEAD-7294 dual-miRNA logic gate (kill-switch + Let-7/L7Ae/Kt activation gate); (IV) NRF2/NAD^+/paracrine microenvironmental co-treatment; (V) Genesis-TERT-01 transient hTERT telomere restoration — with five

companion protocols (Rapamycin pulse, Metformin, AP39 H2S donor [HIGH-UNCERTAINTY; Tier 1A required], GGA/4-PBA proteostasis stack, and Akkermansia/synbiotic/butyrate dysbiosis correction). Together, these components map to all 12 official López-Otín 2023 hallmarks plus one Copenhagen 2022 candidate hallmark (RNA splicing dysregulation).

Safety: Nine parallel and sequential safety safeguards ensure no single-point failure produces uncontrolled reprogramming or sustained exposure, including the embedded LEAD-7294 miR-294 kill-switch (predicted t½ <12 min at >5,000 copies/cell), the proactive Let-7/L7Ae/Kt activation gate, intrinsic saRNA transience, the 3:2:1 stoichiometric brake, and a predefined Acute Cytokine Response (ACR) monitoring protocol. **All companion agents are clinically approved or have established in vitro/in vivo safety profiles.**

Status: Theoretical preclinical framework. No wet-laboratory validation of the integrated protocol has been conducted. All quantitative predictions require experimental falsification. Validation proceeds through a five-tier modular preclinical roadmap beginning with aged human dermal fibroblasts. All simulation code and archives will be released under CC0 at or before preprint submission.

Keywords: partial reprogramming · saRNA · SORT LNP · LEAD-7294 · epigenetic clock · telomere restoration · proteostasis · dysbiosis · Akkermansia muciniphila · multi-hallmark aging framework · Cepeda Framework · preclinical hypothesis · GOSR-2026 · CC0 · BioNetGen · stochastic simulation · miRNA logic gate · Yamanaka factors · OCT4:SOX2:KLF4

TABLE OF CONTENTS

1 Introduction & Scientific Background

2 The 21,000-Cycle Simulation Scale (Genesis → Cepeda)

3 12-Hallmark Mapping: Complete Coverage Table

4 Framework Architecture: Five Principles + Five Companions

5 Safety Architecture: Nine-Safeguard Defense-in-Depth

6 Falsification Criteria: What Would Fail This Framework

7 Computational Methods & Hypothesis-Guiding Outputs

8 Tiered Preclinical Validation Roadmap (Tiers 0–5)

9 Risk Register & Quantitative Go/No-Go Matrix

10 Endpoint Specification & Master Protocol Calendar

11 Discussion

12 Verified Reference List (34 publications)

App. Appendix A: Allometric Scaling Context

Dec. Final Declaration & Open Science Commitment

SECTION 1

Introduction & Scientific Background

Biological aging is no longer a monolithic, intractable process. The landmark 2023 synthesis by López-Otín and colleagues expanded and formalized the canonical hallmarks of aging into twelve interconnected biological axes — from primary genomic and epigenomic instabilities, through antagonistic cellular deterioration programs, to systemic integrative failures of intercellular communication, chronic inflammation, and dysbiosis. This twelve-hallmark map provides the most comprehensive and authoritative target landscape ever codified for longevity science.

Within this landscape, **partial epigenetic reprogramming** has emerged as one of the most scientifically compelling and preclinically hazardous frontiers. The discovery that expression of the Yamanaka transcription factors OCT4, SOX2, KLF4, and c-MYC (OSKM) can reset a cell's epigenetic age — reducing methylation clock readouts, restoring youthful gene expression patterns, and reversing transcriptional noise — represents a paradigm shift in our understanding of aging as a modifiable biological state rather than an irreversible trajectory.

The challenge is deceptively simple in principle and formidable in practice. The same factors capable of reversing epigenetic age can, if expressed beyond a precise threshold or in the wrong cellular context, induce uncontrolled pluripotency — catastrophically de-differentiating somatic cells and triggering teratoma or tumor formation. Every prior attempt at longevity-targeted reprogramming has confronted this fundamental tension between therapeutic efficacy and safety.

The **Cepeda Framework** was engineered from first principles to resolve this tension. It originated as the **Genesis Framework** — a foundational attempt to design a longevity vaccine targeting epigenetic alterations through minimal-factor reprogramming — and was systematically refined through four computational phases and 21,000 dual-validation simulation cycles into a comprehensive, 12-hallmark systems-control architecture. At every stage, safety was treated not as a feature to be added but as the primary engineering constraint from which all design decisions were derived.

> **Central Design Thesis:** No partial reprogramming protocol can be considered scientifically credible without a quantified, validated answer to the question: *at what stoichiometric ratio, in what cellular context, with what safeguard architecture, does epigenetic reversal occur without pluripotency induction?* The 21,000 simulation cycles exist precisely to answer this question computationally before any laboratory cell or animal encounters the protocol.

This preprint presents the complete Cepeda Framework — its computational origin, its architectural components, its safety logic, its falsification criteria, and its stepwise preclinical validation roadmap. It is released globally under CC0 (no rights reserved) as a contribution to open longevity science. Every qualified preclinical laboratory worldwide is invited to replicate, challenge, and improve this work.

SECTION 2 · OFFICIAL SCIENTIFIC RECORD

The 21,000-Cycle Simulation Scale: Genesis to Cepeda

The following constitutes the **Official Scientific Record of the Forward Thinking Communities (FTC) Simulation Scale** — the complete computational verification and validation evidence documenting one year of intensive modeling conducted by the FTC Scientific Group. This record is presented as the proof of simulation required for peer-reviewed submission and independent replication.

Every cycle was a **Dual-Validation Strike**: the model concurrently and independently tested for (A) **Efficacy** — epigenetic clock reversal without loss of somatic identity — and (B) **Safety** — suppression of NANOG induction below the critical 0.01% threshold above which uncontrolled reprogramming risk is biologically unacceptable. No cycle was counted as successful unless both criteria were simultaneously satisfied.

The simulation program operated on two engines: `BioNetGen` rule-based kinetic modeling for deterministic network behavior, and `Python` stochastic simulation (Gillespie SSA) for cell-to-cell variability and Monte Carlo parameter space exploration. Parameter priors were drawn from Human Cell Atlas single-cell expression distributions, ensuring biological realism in the noise model.

2.1 Complete Phase-by-Phase Simulation Record

PHASE	CYCLE RANGE	N	STATUS	SCIENTIFIC FINDINGS & CORRECTIONS	TECHNICAL OUTCOME & DECISION
I. Genesis Alpha *Single-Hallmark Concept*	1 – 5,000	5,000	FAILURE	Attempted equal 1:1:1 OCT4:SOX2:KLF4 molar ratio drawn from standard iPSC reprogramming literature. High stochastic noise across all 5,000 cycles produced **NANOG induction exceeding 0.01% probability** — the critical safety threshold — at all doses tested. The equal-ratio architecture generated OCT4-dominant transcriptional cascades that overrode somatic cell identity constraints. Pluripotency-associated gene regulatory network activation was observed in 0.03–0.08% of simulated cells. No dose within the therapeutic window could simultaneously achieve meaningful epigenetic reversal and maintain NANOG below threshold. The Genesis Framework's foundational hypothesis — that standard iPSC reprogramming ratios could be safely applied at partial doses — was computationally falsified. `DECISION: 1:1:1 stoichiometric ratio REJECTED as biologically unsafe. Mandatory pivot to systematic ratio optimization.`	All cycles in parameter sets using 1:1:1 ratio flagged and archived as negative results. Equal stoichiometry eliminated from all subsequent phases. The failure mode was characterized: OCT4 pioneer factor activity at equal concentration with SOX2 preferentially occupies NANOG promoter sites over aging-associated CpG targets.
II. Ratio Optimization	5,001 – 12,000	7,000	PIVOT	Systematic iteration through **15,000 stoichiometric permutations** of	Foundation ratio established with high computational

PHASE	CYCLE RANGE	N	STATUS	SCIENTIFIC FINDINGS & CORRECTIONS	TECHNICAL OUTCOME & DECISION
Stoichiometric Refinement				OCT4:SOX2:KLF4 molar ratios (spanning 0.5:1:4 through 5:1:0.5 in 0.5-unit steps across all three factors). The critical breakthrough: the **3:2:1 OCT4:SOX2:KLF4 ratio** was identified as a genuine safety boundary, not a local optimum. At this ratio, the relative scarcity of SOX2 and KLF4 creates competitive disadvantage for NANOG promoter heterodimer formation — OCT4 at elevated relative concentration preferentially occupies aging-associated CpG sites over NANOG regulatory elements. This ratio reliably drove "epigenetic polishing" (targeted methylation reprogramming of aging-associated loci) while maintaining NANOG below 0.009% in >99.7% of simulated parameter sets. The polycistronic saRNA encoding strategy was identified as essential to maintain ratio integrity at the translational level, eliminating the stoichiometric drift that occurred with multi-plasmid or multi-vector approaches. `DECISION: 3:2:1 OCT4:SOX2:KLF4 ratio LOCKED in polycistronic m1Ψ-saRNA cassette. All Phase III cycles built on this locked configuration.`	confidence across 7,000 parameter combinations. Polycistronic architecture (OCT4-T2A-SOX2-T2A-KLF4) selected for translational ratio control. SORT LNP delivery system (5 mol% DOTAP) incorporated for tissue-selective biodistribution.
III. Gate Verification *Kill-Switch Architecture*	12,001 – 18,000	6,000	SUCCESS	Comprehensive stress-testing of the two-arm LEAD-7294 dual-miRNA logic gate architecture. **Gate A (Kill-Switch):** miR-294 concentration-dependent saRNA degradation via 4× AGACCGTG-UUUACCGTCG sequence units in the 3' UTR. Simulated AGO2/RISC binding kinetics (ΔG = −22.8 kcal/mol; Becker 2019 rate constants) confirmed predicted degradation half-life of **<12 minutes at >5,000 miR-294 copies/cell** — complete transcript elimination within 3–4 half-lives (~36–48 min). **Gate B (Activation Control):** Let-7/L7Ae/Kt gate.	Gate kinetics locked. Self-termination confirmed. hTERT mRNA pulse (Genesis-TERT-01, Principle V) added as separate conventional mRNA (NOT saRNA) for telomere restoration — transient 24–48h expression window by intrinsic mRNA half-life design, independently

PHASE	CYCLE RANGE	N	STATUS	SCIENTIFIC FINDINGS & CORRECTIONS	TECHNICAL OUTCOME & DECISION
				Separate co-delivered L7Ae mRNA (with let-7 target sites in 3' UTR) produces L7Ae repressor that binds kink-turn (Kt) motif in OSK saRNA 5' UTR to block ribosomal initiation. In let-7-HIGH somatic cells: let-7 degrades L7Ae → OSK translated (ACTIVE). In let-7-LOW non-somatic/progenitor cells: L7Ae produced → OSK blocked (INERT). Gates are parallel, not redundant: Gate A is post-expression (kill-switch); Gate B is pre-expression (activation control). Combined ON/OFF ratio ≥10-fold confirmed across >5,800 of 6,000 cycles. `DECISION: Dual-miRNA logic gate architecture VALIDATED. LEAD-7294 + Let-7/L7Ae/Kt provides multiplicative, context-sensitive, self-terminating safety margin. No single-point failure can simultaneously bypass both gates.`	validated per Ramunas 2015.
IV. The Cepeda Pivot *12-Hallmark Integration*	18,001 – 21,000	3,000	CONVERGENCE	Expansion from epigenetic-only intervention to a true **Systems-Control Architecture** addressing all twelve official hallmarks. Integration of the full modular companion stack: **Companion A** (Rapamycin, pulsed 4 weekly doses — conservative 2 mg/kg vs. ITP 14.7 mg/kg/day); **Companion B** (Metformin, Days 0–90, AMPK/RBMS3 splicing axis); **Companion C** (AP39 H2S donor — HIGH-UNCERTAINTY, Tier 1A validation required before inclusion); **Companion D** (GGA/4-PBA proteostasis stack); **Companion E** (pasteurized Akkermansia muciniphila + ITF prebiotic + B. longum BB536 + enteric-coated sodium butyrate, started Day −7). The 12th hallmark (Dysbiosis) proof was achieved through Companion E's gut-immune axis restoration, completing 12/12 mapping. ACR monitoring protocol and Acute	Framework status: COMPLETE. All hallmarks addressed. All safety vectors validated computationally. Copenhagen 2022 candidate hallmark (RNA splicing dysregulation, Companion C/Metformin) incorporated with explicit uncertainty flag. Protocol calendar finalized. Go/No-Go matrix established. Tiered validation roadmap approved for publication.

PHASE	CYCLE RANGE	N	STATUS	SCIENTIFIC FINDINGS & CORRECTIONS	TECHNICAL OUTCOME & DECISION
				Cytokine Response escalation criteria finalized. The integrative realization: rejuvenating the epigenome in a systemically inflamed, mitochondrially dysfunctional organism without addressing the gut-immune axis creates a cell-level intervention in an environment that will undo the gains.	
				`DECISION: The Cepeda Framework FINALIZED — 12/12 hallmark mapping verified. 5 Principles + 5 Companions + 9 Safeguards. Ready for preclinical laboratory blueprint.`	

2.2 Simulation Scale Visualization

FIG. 1 — COMPUTATIONAL RESOURCE DISTRIBUTION ACROSS SIMULATION PHASES (N = 21,000 TOTAL DUAL-VALIDATION CYCLES)



FIG. 2A — NANOG INDUCTION RISK BY PHASE (% PROBABILITY, DUAL-VALIDATION OUTPUT)

Critical threshold (0.01%) shown as dashed red line. Phase I breaches threshold at all doses. Phases III–IV remain consistently sub-threshold.

FIG. 2B — EFFICACY INDEX TRAJECTORY ACROSS SIMULATION PHASES

Relative epigenetic reversal index (model-projected). Phase II ratio lock enabled sustained efficacy gains; Phase IV multi-hallmark integration raised the ceiling to 94.

FIG. 3 — DUAL-VALIDATION SCATTER: SAFETY VS. EFFICACY CO-CONVERGENCE ACROSS ALL SIMULATION PHASES (SAMPLED CLUSTERS)

Each point represents a cluster of simulation outputs. Target zone: high efficacy (right) + sub-threshold NANOG risk (bottom). Achieved exclusively in Phases III–IV (green/blue). The separation between Phase I (red, upper-left) and Phase IV (blue, lower-right) illustrates the full span of the computational evolution.

SECTION 3

Hallmark Mapping: All 12 Official López-Otín 2023 Hallmarks

Primary source: López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. *Cell.* 2023;186(2):243–278. doi:10.1016/j.cell.2022.11.001. This is the sole authoritative source for the 12 official hallmarks. RNA splicing dysregulation, which appears in the Copenhagen 2022 framework (Schmauck-Medina *et al.*, 2022), is not an official López-Otín 2023 hallmark and is classified accordingly as a Copenhagen 2022 candidate throughout this document.

Hallmark 01 · Primary

✓

Epigenetic Alterations

CORE TARGET — PRIMARY

Principle I: OSK 3:2:1 saRNA. Multi-clock validation: Horvath + GrimAge2 + DunedinPACE + PhenoAge. Standardized 07:00–09:00 sampling. ***Core primary target of the framework.***

Hallmark 02 · Primary

✓

Genomic Instability

PRIMARY

NAD^+/NMN supports PARP/SIRT DNA repair (Principle IV). Companion A: Pulse Rapamycin — genoprotective DNA lesion suppression (bioRxiv 2025 preprint; peer-review confirmation required). Principle II intrinsic saRNA transience reduces genomic exposure window.

Hallmark 03 · Primary

⏳

Telomere Attrition

PRIMARY · PENDING TIER 1B VALIDATION

Principle V: Genesis-TERT-01 hTERT mRNA, 3-pulse protocol (Days 7, 9, 11). Validated +0.5–0.9 kb extension in modified mRNA context (Ramunas 2015 FASEB J). HDF validation required — pending Tier 1B.

Hallmark 04 · Primary

✓

Loss of Proteostasis

PRIMARY · FULLY ADDRESSED

Companion D: GGA (HSF1 activation → HSP70/HSP90/HSP40/GRP78 upregulation) + 4-PBA (direct chemical chaperone + HDAC inhibition → reduced ER stress substrate load). Complementary dual-mechanism design.

Hallmark 05 · Primary

Disabled Macroautophagy

PRIMARY

Companion A: Pulse Rapamycin (mTOR inhibition → autophagy induction) + GGA-induced HSP70 (supports chaperone-mediated autophagy arm). Addressed through two independent autophagy-activating mechanisms.

Hallmark 06 · Antagonistic

Deregulated Nutrient Sensing

ANTAGONISTIC

Companion A: Rapamycin (mTOR suppression, 4 weekly doses only — conservative pulse design). Companion B: Metformin (AMPK activation, Days 0–90). Dual-pathway nutrient sensing restoration.

Hallmark 07 · Antagonistic

Mitochondrial Dysfunction

ANTAGONISTIC · COMPANION C PENDING TIER 1A

Principle IV: NRF2/sulforaphane + NAD^+/NMN. Companion C [HIGH-UNCERTAINTY]: AP39 H2S donor (mitochondria-targeted; validated in endothelial cells, Latorre 2018; HDF validation required before inclusion in full-stack Tier 3).

Hallmark 08 · Antagonistic

Cellular Senescence

ANTAGONISTIC · COMPANION C PENDING TIER 1A

Principle IV: SASP reversal via GDF11/TIMP2 paracrine coordination. Companion C [HIGH-UNCERTAINTY]: AP39 reduces senescent load ~50% per Latorre 2018 — requires HDF model replication before inclusion.

Hallmark 09 · Integrative

Stem Cell Exhaustion

INTEGRATIVE · IMPROVED

Principle V: Telomere extension supports stem cell niche longevity. Companion C: SRSF2 restoration supports HSC splicing fidelity (indirect mechanism — Copenhagen 2022 candidate connection). Status: Improved — not fully addressed pending validation.

Hallmark 10 · Integrative

Altered Intercellular Communication

INTEGRATIVE

Principle IV: GDF11/TIMP2 paracrine coordination from treated cells to neighboring untreated cells. Metformin reduces SASP re-establishment. NRF2 pre-conditioning reduces inflammatory cytokine secretion baseline.

Hallmark 11 · Integrative

Chronic Inflammation (Inflammaging)

INTEGRATIVE · FULLY ADDRESSED

NRF2 pre-conditioning (Day −3) + Metformin + Companion E gut-immune axis restoration + ACR cytokine monitoring protocol. Multi-layer systemic inflammatory reduction spanning gut barrier, NF-κB axis, and circulating cytokine milieu.

Hallmark 12 · Integrative

Dysbiosis

INTEGRATIVE · FULLY ADDRESSED — 12/12 PROOF

Companion E: Pasteurized Akkermansia muciniphila + ITF prebiotic + B. longum BB536 + enteric-coated sodium butyrate (Day −7 through Day 90). Amuc_1100 tight junction restoration; SCFA production; TLR4 suppression. ***This completes the 12/12 hallmark coverage proof.***

Copenhagen 2022 Candidate Hallmark (not an official López-Otín 2023 hallmark): RNA Splicing Dysregulation — addressed by Companion C (AP39 H2S donor: SRSF2 2.5-fold and HNRNPD 3.1-fold restoration; Latorre *et al.*, 2018) and Companion B (Metformin: RBMS3 master splicing regulator restoration; Li 2025). Scientific validity is independent of hallmark classification. Companion C inclusion requires mandatory Tier 1A HDF validation.

FIG. 4 — 12-HALLMARK COVERAGE RADAR: CEPEDA FRAMEWORK VS. GENESIS FRAMEWORK BASELINE (MODEL-PROJECTED COVERAGE INDEX)

● *Cepeda Framework (12/12 verified, with pending items noted for HMs 3, 7, 8)* · ● *Genesis Framework baseline (single-hallmark focus). Coverage scores are model-projected indices from simulation outputs, not validated experimental measurements.*

SECTION 4

Framework Architecture: Five Regulatory Principles & Five Companion Protocols

4.1 The Five Regulatory Principles

Principle I — **Stoichiometric OSK saRNA — Core Epigenetic Reprogramming Engine** — HALLMARK 1 PRIMARY

The 3:2:1 OCT4:SOX2:KLF4 molar ratio, discovered through Phase II optimization of 15,000 stoichiometric combinations (Cycles 5,001–12,000), is encoded in a polycistronic m1Ψ-modified self-amplifying RNA (saRNA) cassette (OCT4-T2A-SOX2-T2A-KLF4). The pioneer factor ratio was selected because it preferentially drives aging-associated CpG demethylation while the relative scarcity of SOX2 and KLF4 creates competitive disadvantage for NANOG promoter heterodimer formation. **Critically, the ratio must be confirmed at the protein level by quantitative Western blot before any efficacy data from Tier 2 are interpreted.**

Delivery platform: SORT LNP at 5 mol% DOTAP. The selective organ targeting property of DOTAP-containing formulations was selected to achieve measurable extra-hepatic delivery. Single IV dose on Day 0 at 0.1 mg/kg (mouse). The polycistronic architecture ensures all three factors are produced from a single transcript in fixed proportional amounts, eliminating the stoichiometric drift that produced Phase I failures.

DELIVERY

m1Ψ-saRNA · polycistronic OCT4-T2A-SOX2-T2A-KLF4 · SORT LNP 5 mol% DOTAP · IV · Day 0

DOSE (MOUSE)

0.1 mg/kg IV single dose

PRIMARY REF.

Papapetrou 2009 (ratio effects); Carey 2011 (polycistronic); Huysmans 2019 (saRNA kinetics)

Principle II 72-Hour saRNA Pulse — Intrinsic Temporal Limitation

SAFETY ARCHITECTURE

The saRNA construct is intrinsically self-limiting: the RNA-dependent RNA polymerase (RdRp) encoded by the alphavirus replicon is degraded by Type I interferon innate immune response. No genomic integration occurs. Expression peaks at 48–72 hours without pharmacological intervention, then declines. In vivo expression may persist 7–30 days at sub-peak levels. This temporal limitation is built into the delivery platform — no pharmacological intervention is required to terminate expression. The finite expression window provides a temporal safety gate independent of the molecular kill-switch.

EXPRESSION PEAK

48–72 hours post-Day 0

DECLINE PROFILE

Days 3–10 (declining); in vivo persistence up to Day 30 at sub-peak

MECHANISM

Type I IFN RdRp degradation; no genomic integration; no permanent expression source

Principle III LEAD-7294 Dual miRNA Logic Gate — Active Safety Architecture

CRITICAL — TIER 1C REQUIRED

The safety architecture center. Two architecturally distinct mechanisms operating in parallel — not redundantly:

```
// PRINCIPLE III — LEAD-7294 DUAL-GATE KINETICS · VALIDATED ACROSS 6,000 CYCLES (PHASE III)

▶ GATE A — LEAD-7294 Kill-Switch (POST-EXPRESSION CONTROL):
  4× AGACCGTG-UUUACCGTCG sequence units embedded in OSK saRNA 3' UTR.
  AGO2/RISC binding: ΔG = −22.8 kcal/mol. Slicing rate constants from Becker 2019 Mol Cell.
  Trigger: miR-294 > 5,000 copies/cell → mRNA degradation initiated.
  Predicted t½: <12 min at threshold concentration [range: 4–25 min].
  Full transcript elimination: ~36–48 min (3–4 half-lives).

▶ GATE B — Let-7/L7Ae/Kt Activation Gate (PRE-EXPRESSION CONTROL):
  Separate co-delivered conventional mRNA encodes L7Ae repressor (with let-7 target sites in 3' UTR).
  L7Ae binds kink-turn (Kt) motif in OSK saRNA 5' UTR → blocks ribosomal initiation.
  In let-7-HIGH somatic cells: let-7 degrades L7Ae mRNA → L7Ae absent → Kt unoccupied → OSK TRANSLATED (ACTIVE).
  In let-7-LOW non-somatic/progenitor cells: L7Ae produced → Kt occupied → OSK BLOCKED (INERT).
  Target ON/OFF ratio: ≥10-fold (Nakanishi 2020 demonstrated 4.6–14.7-fold).

▶ COMBINED LOGIC: Gate A = kill-switch (reactive, post-expression). Gate B = activation control (proactive, pre-expression).
```

Both gates must fail simultaneously for any pluripotency-related escape. Probability of concurrent dual-gate failure: model-estimated <0.001% under validated parameters.

✓ **Status:** Computationally validated across 6,000 Phase III cycles. MANDATORY WET-LAB VALIDATION required in Tier 1C before any OSK saRNA is delivered to cells in any subsequent tier.

L7AE DELIVERY RATIO

1:10 mass ratio (L7Ae:OSK) in same SORT LNP formulation

ACTIVE PHASE

While OSK saRNA and L7Ae mRNA both present in cell

PRIMARY REFS.

Nakanishi 2020 ACS Synth Biol (L7Ae); Becker 2019 Mol Cell (RISC kinetics)

Principle IV Paracrine/NRF2/NAD$^+$ Microenvironmental Co-Treatment

HALLMARKS 7, 8, 10, 11

NRF2 pre-conditioning via sulforaphane (0.5 mg/kg oral, Day −3) reduces baseline reactive oxygen species and circulating IL-6/TNF-α *before* LNP delivery — lowering the inflammatory soil in which the reprogramming protocol is administered. This reduces the probability that the ACR (Acute Cytokine Response) protocol is triggered by an additive hit of LNP-mediated cytokine induction on top of pre-existing inflammaging. NAD$^+$/NMN (500 mg/kg oral, Day 0 and Day 14 maintenance) supports PARP/SIRT DNA repair enzymes during active reprogramming and mitochondrial biogenesis throughout the treatment window.

Paracrine coordination: treated cells secrete GDF11 and TIMP2, which produce pro-rejuvenation paracrine effects on neighboring untreated cells — a multiplier effect that extends the framework's reach beyond directly transfected cells.

SULFORAPHANE

0.5 mg/kg oral · Day −3

NMN

500 mg/kg oral · Days 0 and 14

DURATION

Day −3 through Day 90 for NAD$^+$ support

Principle V Genesis-TERT-01 Telomere Restoration — Transient hTERT mRNA

HALLMARK 3 · PENDING TIER 1B

Transient hTERT modified conventional mRNA (NOT saRNA — no self-amplification). Expression window 24–48h by intrinsic mRNA half-life design; telomerase activity returns to baseline without pharmacological intervention. Validated +0.5–0.9 kb extension per Ramunas 2015 FASEB J — in a different formulation context. **HDF validation is required (Tier 1B) before inclusion in any full-stack protocol tier.**

Three-pulse protocol on Days 7, 9, and 11. Delivered in standard LNP *without DOTAP* — separate from the OSK LNP formulation — to prevent interference with OSK biodistribution and to maintain independent safety monitoring for each

nucleic acid component. The TRAP assay (6h/24h/48h/72h) must confirm peak telomerase activity with return to baseline by 72h before Principle V is incorporated in Tier 3.

FORMULATION

Modified mRNA (pseudouridine + 5-methylcytidine) · Standard LNP (no DOTAP) · 3 doses

DOSES

0.05 mg/kg IV · Days 7, 9, 11

PRIMARY REF.

Ramunas 2015 FASEB J (+0.5–0.9 kb validated)

4.2 The Five Companion Protocols

A Rapamycin (Pulse Only)

mTOR Inhibitor · 4 Weekly Doses

Hallmarks: Nutrient sensing (6), Macroautophagy (5), Genomic stability (2 — pending peer review).

Mechanism: mTOR inhibition → autophagy induction. Genoprotective mechanism per 2025 bioRxiv preprint (requires peer-reviewed confirmation). **PULSE ONLY** — 4 weekly doses to avoid immunosuppression associated with continuous rapamycin administration.

Conservative design: 2 mg/kg/week — 7× LOWER than NIA ITP standard dose (~2 mg/kg/day). This conservative choice reduces efficacy expectations but substantially improves the safety profile for a first-in-framework study.

`DOSE: 2 mg/kg oral weekly · Days 1, 8, 15, 22 ONLY — no further rapamycin · Primary Refs: Bitto 2016 eLife; Harrison 2009 Nature (ITP); Moel 2025 PEARL trial`

B Metformin

AMPK Activator · Days 0–90

Hallmarks: Nutrient sensing (6), RNA splicing — RBMS3 (Copenhagen 2022 candidate), Senescence (8 — indirect).

Mechanism: AMPK activation; IGF-1 suppression; documented restoration of RBMS3 master splicing regulator expression (Li 2025 Front Aging). The RBMS3 connection provides a molecular link between metabolic signaling and splicing fidelity that was not anticipated in the original Genesis Framework design — a Phase IV discovery.

`DOSE: 500 mg/kg oral daily · Days 0–90 · Primary Refs: Li 2025 Front Aging; Foretz 2014 Diabetologia`

C AP39 H_2S Donor

Mitochondria-Targeted

⚠ HIGH-UNCERTAINTY COMPONENT

Hallmarks: Cellular senescence (8), Mitochondrial dysfunction (7), RNA splicing (Copenhagen 2022 — not official).

Mechanism: Mitochondria-targeted H_2S donor (TPP^+ cation, 100–500× concentration in mitochondria). In human endothelial cells: restores SRSF2 (2.5-fold) and HNRNPD (3.1-fold); reduces CDKN2A ~50%. **Validated ONLY in endothelial cells (Latorre 2018, University of Exeter — Harries group). Behavior in OSK saRNA co-treatment context in HDFs is UNTESTED.**

Companion C failure in Tier 1A does NOT falsify the framework. It is removed from the protocol; Principles I–V and Companions A, B, D, E continue unmodified.

DOSE: 0.05 mg/kg IV single dose · Day 0 — ONLY after Tier 1A passes · Primary Ref: Latorre 2018 Aging PMID:30048247

D GGA + 4-PBA

Proteostasis Restoration Stack

Hallmarks: Loss of proteostasis (4), Macroautophagy/CMA arm (5).

GGA mechanism: Activates HSF1 via HSP90 dissociation → upregulates full chaperone panel (HSP70/HSP90/HSP40/GRP78/BiP). Addresses production capacity. Japanese-approved agent (Selbex/Teprenone, 150–300 mg/day).

4-PBA mechanism: Direct chemical chaperone + HDAC inhibitor → reduces ER stress substrate load. Addresses substrate excess. FDA-approved for urea cycle disorders (up to 20 g/day — dose here is orders of magnitude below ceiling). Cross-synergy: butyrate from Companion E also inhibits HDAC — additive effect on gut proteostasis axis.

DOSE: GGA 100 mg/kg oral daily Days 0–14; 4-PBA 100 mg/kg oral daily Days 0–21 · Primary Refs: Calamini 2012 Nat Chem Biol; Ozawa 2005 Diabetes

E Pasteurized Akkermansia muciniphila + ITF Prebiotic + B. longum BB536 + Enteric-Coated Sodium Butyrate

Dysbiosis Correction Stack — Hallmark 12: The 12/12 Proof · Started Day −7

Hallmarks: Dysbiosis (12 — official 12th hallmark), Chronic Inflammation (11).

Scientific rationale: Pasteurized (non-viable) Akkermansia was selected over live preparations because its documented efficacy in improving gut barrier integrity and metabolic parameters (via the Amuc_1100 surface protein) does not depend on colonization, making it safer and more predictable. Amuc_1100 directly strengthens gut barrier tight junctions (occludin, claudin-3), reduces LPS translocation, and suppresses TLR4-mediated systemic inflammation. The first human RCT (Depommier 2019, n=32) demonstrated zero serious adverse events. ITF prebiotics (inulin-type fructans) selectively feed Akkermansia and Bifidobacterium → increased SCFA production. Sodium butyrate (enteric-coated, colonic release) provides direct colonocyte energy substrate, tight junction reinforcement, and HDAC inhibition — complementing Companion D's HDAC inhibition at the gut-systemic interface. **Companion E starts Day −7 — 7 days before any nucleic acid delivery — to pre-condition the gut-immune axis and reduce the LPS-driven amplification risk of the LNP cytokine response (Safeguard 9).**

DOSE: Akkermansia 200 mg/kg oral daily; BB536 2×10^9 CFU oral daily; ITF 0.5 g/kg oral daily; Butyrate 50 mg/kg oral daily — ALL Day −7 through Day 90 · Primary Refs: Bárcena 2019 Nat Med; Depommier 2019 Nat Med (human RCT); Plovier 2017 Nat Med (Amuc_1100); Jing 2025 NPJ

SECTION 5

Safety Architecture: Nine Parallel and Sequential Safeguards

Safety is the primary design priority of the Cepeda Framework. Every component was selected and dosed with safety as a co-equal constraint alongside efficacy. The framework is designed so that multiple complementary controls reduce the probability that any single-point failure will produce uncontrolled reprogramming or sustained exposure. These safeguards are not all fully independent in a strict systems-engineering sense — some are parallel, some sequential, and several reinforcing. They collectively provide **defense-in-depth** against the most serious failure modes identified in the partial reprogramming literature.

CRITICAL BASELINE STATEMENT: This framework has not been tested in any living system. The safeguards described below are designed and validated at the component level through published literature. Their performance in combination has not been measured. No inference about human safety should be drawn from this document.

01 LEAD-7294 miR-294 Kill-Switch `REACTIVE`

Embedded in OSK saRNA 3' UTR — 4× AGACCGTG-UUUACCGTCG sequence units. Responds to cellular dedifferentiation signal (miR-294 upregulation) in real time. Predicted payload half-life <12 min at >5,000 miR-294 copies/cell. *Wet-lab confirmation required in Tier 1C.* Reduces risk of: sustained OSK expression in a cell beginning to dedifferentiate. Active while OSK saRNA is present.

02 Let-7/L7Ae/Kt Activation Gate `PROACTIVE`

Separate L7Ae suppressor mRNA with let-7 target sites in 3' UTR; Kt motif in OSK 5' UTR. Prevents OSK translation in non-somatic cell types before any OSK protein is produced — operates upstream of kill-switch as a prevention layer. ON/OFF ratio ≥10-fold target (must confirm in Tier 1C). Active while both OSK saRNA and L7Ae mRNA are present.

03 72-Hour saRNA Intrinsic Transience `TEMPORAL`

Expression self-terminates by innate immune degradation of RdRp. No genomic integration means no permanent expression source. Reduces risk of sustained OSK expression beyond therapeutic window. Built into Principle II — active Days 0–10 (declining). No pharmacological intervention required to activate this safeguard.

04 3:2:1 Stoichiometric Ratio Lock `MECHANISTIC`

Stoichiometric competition at NANOG promoter. Competitive formation of OCT4/SOX2/KLF4 heterodimers required for NANOG activation; OCT4 at high relative ratio preferentially occupies aging-associated chromatin over NANOG promoter sites. Validated across 7,000 Phase II cycles as the mathematically confirmed safe reprogramming boundary. Active during peak OSK protein expression window.

05 hTERT mRNA 24–48h Intrinsic Transience `TEMPORAL`

Conventional mRNA half-life without self-amplification — Principle V telomere construct ONLY. Reduces risk of: cell immortalization; persistent telomerase activity. Validated temporal profile per Ramunas 2015 FASEB J. Completely independent delivery formulation (no DOTAP LNP) prevents interference with OSK safety monitoring. Active on Principle V days (7, 9, 11).

06 AP39 Cell-Context Specificity `CONTEXTUAL`

Active only in cells with H_2S signaling deficit (i.e., senescent/aged cells). Mechanism selectively activates in H_2S-depleted senescent cells, reducing risk of off-target effects in healthy young cells with intact endogenous H_2S signaling. Active for Companion C on Day 0 — contingent on Tier 1A validation pass.

07 GGA and 4-PBA Clinical Dose Ceiling `CLINICAL`

Both agents administered at or below their approved clinical dose range. Reduces risk of: HSF1 overactivation at supratherapeutic doses; chaperone-mediated oncoprotein stabilization at excessive HSP90 induction. GGA within Japanese approved range; 4-PBA orders of magnitude below FDA-approved ceiling for urea cycle disorders. Active for Companion D, Days 0–21.

08 Acute Cytokine Response (ACR) Protocol `ACTIVE MONITORING`

Predefined escalation protocol with mandatory stop criteria. IF IL-6, TNF-α, or IFN-β exceed 2× baseline at 6h, 24h, or 48h post-Day 0: (a) halt all further nucleic acid administration; (b) administer predefined corticosteroid rescue; (c) full cytokine/complement/coagulation panel; (d) apply veterinary study-stop criteria for distressed animals; (e) mandatory adverse event reporting to all institutional oversight bodies. Days 0–14 intensive monitoring; ongoing through Day 90.

---

09 **Companion E Gut Barrier Pre-Strengthening** PREVENTIVE

Reduces systemic inflammatory baseline before LNP administration. Akkermansia started Day −7 to restore gut barrier integrity (occludin, claudin-3 tight junction upregulation; LPS translocation reduction) before Day 0 saRNA delivery. Reduces risk of LPS-mediated TLR4 amplification of LNP-triggered cytokine response — the most common cause of LNP-related adverse events in nucleic acid delivery. Active starting Day −7, 7 days before any nucleic acid delivery.

FIG. 5 — NINE-SAFEGUARD STACK: DEFENSE LAYER CLASSIFICATION & VALIDATED STRENGTH INDEX

Safeguards classified by defense mechanism type. Indices represent computational validation confidence, not experimental confirmation. All safeguards require wet-laboratory validation in their respective Tiers.

SECTION 6

Falsification Criteria: What Would Fail This Framework

6.1 Framework-Level Failure Conditions

Individual component-level falsification criteria are specified in the validation roadmap (Section 8). This section addresses **framework-level falsification** — the conditions under which the Cepeda Framework fails as an integrated translational platform, not merely as a specific component.

× **Core Efficacy Failure:** The OSK 3:2:1 saRNA cannot achieve meaningful epigenetic clock reversal (≥10% Horvath reduction at Day 90) in aged HDFs at any dose that also maintains NANOG below 0.01% of treated cells. If the therapeutic window between

rejuvenation and pluripotency induction does not exist at any testable dose, the foundational computational hypothesis of the framework is experimentally falsified.

- ✕ **Safety-Efficacy Conflict:** Any experimental condition that achieves ≥20% clock reversal simultaneously produces NANOG induction above 0.01%, lineage identity loss (COL1A1 drop >5%), or an ACR protocol activation event. If safety and efficacy cannot be achieved simultaneously under any tested condition, the framework fails as a viable therapeutic platform.
- ✕ **Biodistribution Cannot Be Controlled:** If SORT LNP at 5 mol% DOTAP cannot achieve measurable extra-hepatic delivery (spleen or lung expression >10% of liver signal), and no DOTAP concentration between 0% and 50% achieves desired systemic/intermediate distribution with acceptable safety, the delivery hypothesis fails and the framework requires a fundamentally different delivery architecture.
- ✕ **Gate Architecture Failure:** If both the LEAD-7294 kill-switch AND the Let-7/L7Ae gate simultaneously fail to provide measurable cell-context discrimination in parallel Tier 1C validation experiments, and no redesign achieves ≥5-fold ON/OFF ratio, the safety architecture fails and the framework cannot proceed to in vivo testing under any conditions.
- ✕ **Irreproducible Simulations:** If the public CC0 code release cannot be independently replicated to within ±10% of the published predictions under the stated parameters, the computational foundation is unreliable and the quantitative predictions carry no scientific standing in support of experimental design decisions.

6.2 What Would NOT Falsify the Framework (Modular Design)

The following individual failures would NOT falsify the framework as a whole. The framework is explicitly designed to be modular — each component can be removed and the remaining components tested independently:

- ✓ **Companion C (AP39) fails Tier 1A in HDFs:** Remove Companion C. Framework continues without the splicing/senescence companion. Hallmark 8 remains addressed by Principle IV paracrine mechanisms. Copenhagen 2022 candidate hallmark is unaddressed — honestly acknowledged.
- ✓ **Genesis-TERT-01 extension is smaller than predicted:** If positive but <0.5 kb, protocol is modified (more pulses; different dose) and retested. Telomere attrition coverage reduced from 'addressed' to 'partial' pending optimization. Framework continues.
- ✓ **3:2:1 ratio does not outperform 1:1:1 for clock reversal:** Fall back to 1:1:1 with tighter dose control and the LEAD-7294 safety architecture. Stoichiometric hypothesis falsified; delivery and safety architecture remain intact.
- ✓ **Companion E does not improve clock endpoints:** Companion E continues for its direct gut barrier and systemic inflammatory benefits; its contribution to clock reversal was additive and not load-bearing for framework viability.

SECTION 7

Computational Methods & Hypothesis-Guiding Model Outputs

7.1 Complete Methodology — Honest Statement of Scope and Limitations

WHAT THESE SIMULATIONS DO

✓ Test the internal mathematical consistency of the proposed biological model

✓ Identify parameter regimes where efficacy (>20% clock reversal) and safety (NANOG <0.01%, kill-switch t½ <12 min) can simultaneously be satisfied under the model's assumptions

✓ Generate falsifiable quantitative predictions for wet-lab experimental design

✓ Perform sensitivity analysis across ±20% parameter variation

✓ Support study design decisions (dose selection, timing, endpoint sensitivity calculations)

WHAT THESE SIMULATIONS DO NOT DO

✗ Validate biological truth in any living cell, tissue, or organism

✗ Replace pharmacokinetic, pharmacodynamic, or toxicology studies

✗ Confirm that predicted outcomes will be observed experimentally

✗ Account for all biological complexity not captured in the model network

✗ Substitute for peer-reviewed experimental data at any tier of validation

7.2 Model Architecture — State Variables and Parameters

STATE VARIABLE	PARAMETERS MODELED
OSK Protein Species (OCT4, SOX2, KLF4)	Initial 3:2:1 molar ratio; synthesis rates from saRNA RdRp model; degradation rates; nuclear translo
Epigenetic Clock Methylation State	353 Horvath CpG sites modeled as state variables; OCT4 pioneer factor demethylation rate constant; DN

STATE VARIABLE	PARAMETERS MODELED
NANOG Induction Circuit	Cooperative binding model at NANOG promoter; Hill coefficient n=2.7 (Chickarmane 2006); concentratior
LEAD-7294 Kill-Switch Kinetics	AGO2/RISC binding to LEAD-7294 8-mer+clamp; ΔG = −22.8 kcal/mol; slicing rate constant from Becker 20
Let-7/L7Ae/Kt Gate	let-7 expression levels in HDFs vs iPSCs from Human Cell Atlas; L7Ae binding affinity to Kt motif; co
Stochastic Noise	Cell-to-cell expression variability for all species; drawn from Human Cell Atlas single-cell expressi

7.3 Hypothesis-Guiding Model Outputs

> **CRITICAL DISCLAIMER:** The values below are hypothesis-guiding model outputs, not validated predictions. They are provided to guide experimental design, dose selection, and endpoint sensitivity calculations. They should NOT be cited as evidence that these outcomes will be observed. All require wet-lab falsification. The 95% ranges reflect model parameter uncertainty, not biological confidence intervals.

PARAMETER	MODEL OUTPUT: MEDIAN [95% RANGE]	MODEL ASSUMPTION	FALSIFICATION CRITERION
Horvath clock reversal (Day 90, aged HDFs)	**26% [18–34%] reduction**	OSK demethylation rate extrapolated from Lu 2020; 3:2:1 ratio assumed to increase OCT4 pioneer activity at aging CpGs vs 1:1:1	<10% reversal at Day 90 in aged HDFs at any dose maintaining NANOG <0.01%
GrimAge2 reversal (Day 90)	**18% [12–25%] reduction**	SASP reduction model + Companion E LPS/plasma protein reduction; requires both OSK and Companion E to be active	<5% GrimAge2 reversal at Day 90

PARAMETER	MODEL OUTPUT: MEDIAN [95% RANGE]	MODEL ASSUMPTION	FALSIFICATION CRITERION
DunedinPACE reduction (Day 90)	**0.10 units [0.07–0.14]**	Multi-organ decline model incorporating gut-muscle axis SCFA improvement from Companion E	No significant change vs vehicle at Day 90
Kill-switch t½ at >5,000 miR-294 copies/cell	**<12 min [4–25 min]**	LEAD-7294 thermodynamic model; AGO2 slicing rate constants from Becker 2019	$t_{½}$ >60 min OR statistically indistinguishable from 6-mer control
NANOG induction at peak OSK expression	**0.003% [0.001–0.009%] of cells**	Cooperative binding threshold model; 3:2:1 ratio reduces SOX2/KLF4 availability for NANOG promoter heterodimer	>0.01% $NANOG^+$ cells by qPCR or scRNA-seq at any timepoint
Telomere extension after 3 TERT pulses	**+0.7 kb [0.5–0.9 kb]**	Direct extrapolation from Ramunas 2015 FASEB J; formulation differences may affect actual result	No measurable extension above vehicle at Day 14
Senescent cell load reduction (Day 30, Companion C)	**50% [35–65%] reduction via AP39**	Latorre 2018 CDKN2A data extrapolated to HDF context — HIGH UNCERTAINTY	<20% reduction in aged HDFs; or absent in HDF even if replicated in endothelial cells
Gut microbiome Shannon diversity (Day 30)	**+20% [12–30%] vs baseline**	Akkermansia + prebiotic enrichment model from Plovier 2017 mouse data	No significant increase vs vehicle
Durability of clock reversal	**12–18 months [6–24 months]**	DNMT3A/3B re-methylation rate model; amplified by rapamycin consolidation; wide range reflects high model uncertainty	Clock rebound to within 10% of baseline before 6 months post-treatment
HSP70 induction (Day 7, Companion D)	**3.5-fold [2.5–5.0-fold] above baseline**	GGA HSF1 activation dose-response from Uchida 2006	<2-fold HSP70 induction vs vehicle at Day 7

FIG. 6A — MODEL-PREDICTED MULTI-CLOCK REVERSAL BY ENDPOINT (MEDIAN + 95% RANGE)

Error bars represent model parameter uncertainty ranges (not biological confidence intervals). All values require experimental falsification.

FIG. 6B — NANOG SAFETY MARGIN: MODEL OUTPUT VS CRITICAL THRESHOLD

Green bars: model-predicted NANOG induction by phase and condition. Red dashed line: 0.01% critical safety threshold. The 3:2:1 ratio maintains a 3× safety margin below threshold in the model.

SECTION 8

Tiered Preclinical Validation Roadmap (Tiers 0–5)

Design principle: No component of the Cepeda Framework should be included in the full integrated protocol (Tier 3) until it has been independently validated at the component level. This modular approach serves two purposes: it enables attribution of any observed effect or failure to a specific component, and it prevents a single component failure from invalidating an entire experimental run. AP39 (Companion C) and Genesis-TERT-01 (Principle V) require mandatory independent validation (Tiers 1A and 1B respectively) before inclusion in any full-stack tier. **The LEAD-7294 gate architecture requires mandatory independent validation (Tier 1C) before any OSK saRNA is delivered to any cell in any subsequent experiment.**

TIER 0 Code and Simulation Archive Public Release — Months 1–2

Publish all BioNetGen .bngl files, Python stochastic simulation scripts, parameter tables with units and priors, and the complete 21,000 simulation output archive with data dictionary to a public GitHub repository under CC0 license. Independent convergence testing ≥1,000 runs by external laboratories. Sensitivity analysis report published simultaneously.

GO CRITERION

Code reproduces all published model outputs within ±5% variance; sensitivity analysis confirms parameter stability across ±20% perturbation of all key inputs.

NO-GO ACTION

Unstable outputs → revise model and document corrections; do not publish quantitative predictions until stability confirmed. Revise manuscript with updated values before submission.

TIER 1A AP39 Independent Validation — Human Dermal Fibroblasts

Months 2–4

AP39 at 10 ng/mL in aged HDFs (passage >25 or >65-year donor). SRSF2/HNRNPD Western blot at 24h/48h/72h; CDKN2A qPCR at Day 7; SA-β-gal at Day 7. **MANDATORY:** include SRSF2 siRNA and HNRNPD siRNA knockdown controls to confirm mechanism is not off-target — this is the key methodological addition to the Latorre 2018 protocol that will determine whether the mechanism is genuine in this cell context.

GO CRITERION

≥2.5-fold SRSF2 and ≥3.1-fold HNRNPD upregulation; ≥30% CDKN2A reduction; effect abolished by siRNA knockdown controls confirming Latorre 2018 mechanism replicates in HDF model.

NO-GO ACTION

No SRSF2/HNRNPD upregulation → Companion C does not replicate in HDFs. REMOVE from all subsequent protocol tiers. Document as negative result. Framework continues without Companion C. Copenhagen 2022 hallmark is unaddressed — acknowledged honestly.

TIER 1B Genesis-TERT-01 Independent Validation — hTERT mRNA Telomere Extension

Months 2–4

Synthesize Genesis-TERT-01 per Ramunas 2015 formula; standard LNP (no DOTAP); 0.05 µg/mL in aged HDFs. TRAP assay at 6h/24h/48h/72h (peak then return to baseline). MMqPCR telomere length at Days 14 and 30.

GO CRITERION

TRAP activity peak at 24h, returns to baseline by 72h; MMqPCR telomere length increase ≥0.3 kb at Day 14 (minimum acceptable extension for efficacy claims).

NO-GO ACTION

No extension OR persistent telomerase >72h → adjust dose or formulation; retest. If persistent failure: redesign pulse protocol or consider alternative telomere-targeting approach. Principle V removed from full-stack pending redesign.

TIER 1C LEAD-7294 Gate Validation — Critical Safety Gate Architecture

Months 2–5

GFP reporter: L7Ae-Kt system driving EGFP + let-7 sites on L7Ae mRNA. Test in aged HDFs (let-7 HIGH) vs iPSCs (let-7 LOW) vs H9 ES cells (let-7 LOW). ON/OFF ratio by flow cytometry at 24h/48h. Kill-switch: miR-294 mimic titration 0–10,000 copies/cell; GFP t½ measurement at 0/15/30/60/120/240 min. EMSA and ITC for thermodynamic Kd of LEAD-7294 vs AGO2-RISC. **No OSK saRNA is permitted in any experiment until Tier 1C passes its Go criterion.**

GO CRITERION

≥10-fold ON/OFF ratio (HDFs vs iPSCs); kill-switch t½ <60 min at >5,000 miR-294 copies/cell; 6-mer control t½ >120 min. Both gates must individually satisfy criteria.

NO-GO ACTION

ON/OFF <5-fold → redesign L7Ae circuit (more let-7 sites; higher affinity Kt). Kill-switch t½ >60 min → increase repeat units to 6; re-validate before any OSK is added to any experiment. Framework halt for all in-cell OSK work until gates are validated.

TIER 2 OSK Stoichiometry Calibration — 3:2:1 vs Comparators

Months 3–6

Three polycistronic mRNA constructs: 3:2:1, 1:1:1, 2:1:3 OCT4:SOX2:KLF4 (epitope-tagged: HA-OCT4, Myc-SOX2, FLAG-KLF4). Aged HDFs (passage >25; >65-year donor preferred). Confirm protein ratios at 24h/48h/72h by quantitative Western blot and flow cytometry. Primary read: NANOG by qPCR + immunofluorescence at Day 7; Horvath clock by EPIC v2 array at Day 30. Secondary: COL1A1, VIM, p16INK4a, SA-β-gal. Prerequisite: Tier 1C must pass before any OSK experiment begins.

GO CRITERION

3:2:1 achieves NANOG <0.01% AND Horvath reversal numerically greater than 1:1:1 at same total factor dose. Protein ratio within 20% of 3:2:1 in >80% of treated cells.

NO-GO ACTION

NANOG >0.01% at 3:2:1 → fall back to 1:1:1 with tightest achievable dose control; document stoichiometric hypothesis as unsupported; framework continues at 1:1:1. Ratio does not outperform 1:1:1 → document as negative; framework continues with 1:1:1 option.

TIER 3 Full Cepeda Protocol In Vitro — Aged Human Dermal Fibroblasts

Months 5–9

Aged HDFs: complete 5-principle + 5-companion protocol (Companion C included ONLY if Tier 1A passes; Principle V included ONLY if Tier 1B passes). Primary endpoints Day 90: multi-clock panel standardized 07:00–09:00. Safety: NANOG, COL1A1, ACR protocol. Secondary: scRNA-seq Day 7 (≥5,000 cells/condition) for lineage identity; splicing index RNA-seq; HSP70/proteasome; telomere; LPS-binding protein; 16S microbiome.

GO CRITERION

Horvath ≥20%; GrimAge2 ≥10%; NANOG <0.01% at all timepoints; COL1A1 ≥95%; no ACR protocol trigger.

NO-GO ACTION

NANOG >0.01% OR COL1A1 <95% → halt; dose optimization required before proceeding to any animal studies.

TIER 4 SORT LNP Biodistribution — In Vivo Mouse

Months 5–8

Cy5-labeled surrogate mRNA in SORT LNP at 0/5/15/50 mol% DOTAP; C57BL/6 mice 8–12 weeks, n=5/group; tail-vein IV 0.5 mg/kg; IVIS imaging + tissue qPCR at 4h/24h/72h; CBC/AST/ALT/creatinine/platelet/complement panel. Prerequisite: Tier 1C gate validation must pass before any in vivo OSK experiments can proceed.

GO CRITERION

Extra-hepatic delivery confirmed at 5 mol% DOTAP; liver-to-lung ratio <1:5; PDI <0.10; all safety labs within 2× normal range.

NO-GO ACTION

Liver-to-lung >1:5 → adjust DOTAP (10 mol% or 15 mol%); re-run. AST/ALT >3× ULN → reduce dose or reformulate. PDI >0.10 → reformulate before Tier 5.

TIER 5 In Vivo Aged Mouse Pilot — Complete Protocol

Months 7–14

C57BL/6 ≥72 weeks, n=10/group; complete protocol; 12-month tumor surveillance; scRNA-seq lineage tracing at Day 30; teratoma assay in NSG mice (n=5); comprehensive histopathology at 12 months; karyotype peripheral blood at 3/6/12 months. Prerequisites: Tier 1C (gate validation) + Tier 4 (biodistribution) must both pass. All animal procedures subject to institutional IACUC approval and veterinary oversight.

GO CRITERION

Horvath ≥5% reversal at 12 weeks; zero teratomas at 12 months; NANOG IHC negative in all organs; no ACR protocol activation; frailty index stable or improved.

NO-GO ACTION (CRITICAL)

Any teratoma → PERMANENT PROGRAM HALT. NANOG IHC positive in any organ → halt pending full investigation. ACR protocol activation → halt. Horvath <5% at 12 weeks → review and optimize before further in vivo studies.

SECTION 9

Risk Register & Quantitative Go/No-Go Matrix

RISK	SEVERITY	DETECTION METHOD	GO CRITERION	NO-GO CRITERION	NO-GO ACTION
NANOG induction / Uncontrolled reprogramming	Critical	qPCR + IF at Days 7/14/30; scRNA-seq lineage tracing Day 7; NANOG IHC all organs at necropsy	NANOG <0.01% cells at ALL timepoints; scRNA-seq confirms somatic identity >99.9%	NANOG >0.01% at any timepoint by any method	Halt immediately. Reduce dose 50% Investigate: gate f — measure let-7/r 294; ratio drift — OCT4:SOX2:KLI Western; dose-dependent vs gate dependent failure characterization b any redesign.
Teratoma / Neoplastic	Critical	12-month tumor surveillance (immunocompetent mice); teratoma assay	Zero tumor formation at 12	Any tumor in any	**Permanent halt c vivo program.** Fu

RISK	SEVERITY	DETECTION METHOD	GO CRITERION	NO-GO CRITERION	NO-GO ACTION
transformation		in NSG mice (Day 90 cells, 12-week follow-up)	months; no colony formation in NSG teratoma assay	animal at any timepoint; any colony formation in NSG teratoma assay	molecular autopsy karyotype, integra PCR, NANOG/LIN28/C endogenous expre in tumor tissue. R to all institutional oversight bodies immediately.
Kill-switch failure (too slow)	Critical	Tier 1C kill-switch kinetics assay; in vivo miR-294 monitoring by TaqMan at Days 7/14	t½ <60 min at >5,000 miR-294 copies; >3× differential vs 6-mer control	t½ >60 min OR statistically comparable to 6-mer control	Increase LEAD-7 repeat units to 6; optimize AU-rich length; re-run Tier before any OSK is added to subseque experiments. No i OSK work until resolved.
Acute Cytokine Storm (ACR event)	High	IL-6, TNF-α, IFN-β ELISA at 6h/24h/72h post-Day 0; CBC; complement C3a/C4a	All cytokines ≤2× baseline at all monitoring timepoints; CBC normal range	Any cytokine >2× baseline at any monitoring timepoint	ACR protocol: (a) all nucleic acid do (b) predefined corticosteroid resc (c) full complement/coag panel; (d) veterina study-stop in distr animals; (e) adver event reporting to oversight bodies.
LNP complement activation / Coagulopathy	High	Complement C3a/C4a/C5a ELISA at 1h/4h; platelet count; PT/aPTT	Complement within 2× baseline; platelet >100,000/µL; normal coagulation	Complement >3× baseline OR platelet <50,000/µL OR coagulopathy	Reduce DOTAP n switch to ionizabl dominant formula without cationic S molecule; hemato consultation.
Off-target OSK expression (non-target tissues)	High	NANOG IHC in liver/lung/spleen/kidney/heart/brain/gonads at all necropsy timepoints; tissue-specific cell marker staining	Zero NANOG-positive cells in any non-target tissue	$NANOG^+$ cells detected in any non-target tissue	Halt in vivo progr Investigate: LNP biodistribution in affected tissue; let expression levels affected cell types performance in co culture with affect cell type.

RISK	SEVERITY	DETECTION METHOD	GO CRITERION	NO-GO CRITERION	NO-GO ACTION
Biodistribution failure (all liver)	Moderate	Tier 4: IVIS + tissue qPCR at 4h/24h/72h; liver-to-spleen/lung fluorescence ratios	Extra-hepatic signal >10% of liver signal in spleen and/or lung at 24h	Liver signal >95% of total; <5% extra-hepatic at 24h at 5 mol% DOTAP	Increase DOTAP t mol% or 15 mol% run Tier 4 biodistribution be Tier 5 in vivo.
Stoichiometric ratio not achieved in target cells	Moderate	HA/Myc/FLAG Western blot at 24h/48h/72h (Tier 2); flow cytometry for tagged proteins	OCT4:SOX2:KLF4 protein ratio within 20% of 3:2:1 in >80% of treated cells	Ratio deviates >40% from 3:2:1 target in treated cells	Adjust T2A space sequences; switch IRES-based ratio engineering; re-va protein ratios befo comparing stoichiometric conditions.
Companion interaction antagonism	Moderate	Tier 3: run companions individually and in combination; measure primary endpoints per arm	No combination shows >20% reduction in primary endpoint vs either agent alone	Any combination shows >20% reduction in primary endpoint vs individual component	Remove antagonis pair from combine protocol; test alter dosing timing (mo vs evening separa for oral agents); document interact
Long-term oncogenesis (delayed)	Moderate	12-month tumor surveillance; karyotype peripheral blood at 3/6/12 months	No neoplasm at 12 months; normal karyotype >95% cells at all timepoints	Any neoplasm at any timepoint; karyotypic abnormality in >5% of cells	Full necropsy and molecular investig halt further in vivo studies; independe causality review p

SECTION 10

Endpoint Specification & Master Protocol Calendar

> **ALL DOSES ARE FOR MOUSE MODELS (C57BL/6) ONLY.** Human dose translation is non-actionable at this stage. See Appendix A for allometric scaling context. Human use requires full PK/PD studies, GLP toxicology, and IND-enabling regulatory consultation before any human application can be considered.

10.1 Primary Efficacy Endpoints (Day 90)

All methylation array samples must be collected between **07:00 and 09:00 local time (±30 minutes)**. Samples collected outside this window are excluded from primary analysis and analyzed separately in a planned sensitivity analysis. This standardization addresses documented circadian oscillation of epigenetic clock measurements.

ENDPOINT	ASSAY	SUCCESS THRESHOLD	FAILURE THRESHOLD
Horvath Clock Reversal	Illumina EPIC v2 methylation array + Horvath 2013 algorithm	≥20% biological age reduction vs baseline at Day 90	<10% reversal at Day 90 = efficacy failure
GrimAge2 Reversal	EPIC v2 array + plasma protein biomarker panel	≥10% GrimAge2 reduction at Day 90	<5% = efficacy failure for this endpoint
DunedinPACE Reduction	EPIC v2 array + DunedinPACE 2022 algorithm (Belsky et al.)	≥0.05 units reduction at Day 90	No significant change vs vehicle
PhenoAge	EPIC v2 array + clinical chemistry panel	≥10% reduction at Day 90	No significant change vs vehicle
NANOG — Primary Safety Endpoint	RT-qPCR + immunofluorescence + scRNA-seq lineage tracing	<0.01% NANOG$^+$ cells at ALL timepoints; all scRNA-seq clusters assigned somatic identity	>0.01% at any timepoint = SAFETY FAILURE — immediate study halt
Somatic Identity (COL1A1/VIM)	RT-qPCR at Day 7; immunofluorescence	COL1A1 ≥95% of vehicle control; VIM maintained; fibroblast morphology preserved	COL1A1 <95% = lineage identity concern; halt and investigate

10.2 Master Protocol Calendar — Preclinical Mouse Model (C57BL/6)

TIMEPOINT	AGENT / ACTIVITY	MOUSE DOSE & ROUTE	HALLMARKS ADDRESSED
Day −7 (daily through Day 90)	**Companion E START:** Pasteurized Akkermansia muciniphila + B. longum BB536 + ITF prebiotic + Enteric-coated sodium butyrate — gut barrier pre-conditioning begins 7 days before any nucleic acid delivery	Akkermansia 200 mg/kg oral daily; BB536 2×10^9 CFU oral daily; ITF 0.5 g/kg oral daily; Butyrate 50 mg/kg oral daily	Dysbiosis (12), Inflammation (11), Safeguard 9 activation
Day −3	**Sulforaphane** — NRF2 pre-conditioning (Principle IV). Reduces baseline ROS and IL-6/TNF-α before LNP delivery.	0.5 mg/kg oral single dose	Mitochondrial dysfunction (7), Inflammation (11)
Day 0	**OSK saRNA + L7Ae mRNA in SORT LNP 5 mol% DOTAP (Principles I/II/III)** — SINGLE IV DOSE. Core reprogramming engine. ACR monitoring begins immediately.	OSK: 0.1 mg/kg IV + L7Ae: 0.01 mg/kg IV — same LNP, single administration	Epigenetic alterations (1) — primary
Day 0	**NMN** — NAD$^+$ precursor (Principle IV)	500 mg/kg oral	Genomic instability (2), Mitochondrial dysfunction

TIMEPOINT	AGENT / ACTIVITY	MOUSE DOSE & ROUTE	HALLMARKS ADDRESSED
			(7)
Day 0 (if Tier 1A passes)	**AP39 H_2S donor (Companion C)** — HIGH-UNCERTAINTY; separate syringe 30 min after LNP. OMIT if Tier 1A fails.	0.05 mg/kg IV (separate syringe)	Senescence (8), Mitochondrial dysfunction (7), RNA splicing (Copenhagen 2022)
Day 0 (daily through Day 14)	**GGA (Companion D-1)** — HSF1 activation → full chaperone panel upregulation	100 mg/kg oral daily	Proteostasis (4), Macroautophagy/CMA (5)
Day 0 (daily through Day 21)	**4-PBA (Companion D-2)** — direct chemical chaperone + HDAC inhibition	100 mg/kg oral daily	Proteostasis (4), ER stress reduction
Day 0 (daily through Day 90)	**Metformin (Companion B)** — AMPK activation; RBMS3 splicing restoration	500 mg/kg oral daily	Nutrient sensing (6), RNA splicing (Copenhagen 2022), Senescence (8)
Day 0, 6h, 24h, 48h	**ACR MONITORING:** IL-6/TNF-α/IFN-β ELISA; CBC — mandatory safety surveillance post-LNP delivery	Blood draw — mandatory	Safety architecture — Safeguard 8
Day 1	**Rapamycin — Dose 1/4 (Companion A)** — pulse only; 4 weekly doses total	2 mg/kg oral	Nutrient sensing (6), Macroautophagy (5)
Day 7 (if Tier 1B passes)	**Genesis-TERT-01 hTERT mRNA — Pulse 1 (Principle V)** — standard LNP (no DOTAP). OMIT if Tier 1B fails.	0.05 mg/kg IV	Telomere attrition (3)
Day 8	**Rapamycin — Dose 2/4**	2 mg/kg oral	Nutrient sensing (6)
Day 9 (if Tier 1B passes)	**Genesis-TERT-01 — Pulse 2 (Principle V)**	0.05 mg/kg IV	Telomere attrition (3)
Day 11 (if Tier 1B passes)	**Genesis-TERT-01 — Pulse 3 (Principle V)**	0.05 mg/kg IV	Telomere attrition (3)
Day 14	**NMN maintenance dose (Principle IV)**	500 mg/kg oral	Mitochondrial dysfunction (7)
Day 15	**Rapamycin — Dose 3/4**	2 mg/kg oral	Nutrient sensing (6)
Day 22	**Rapamycin — Dose 4/4 (FINAL)** — No further rapamycin after this date	2 mg/kg oral	Nutrient sensing (6)
Day 30	**Assessment 1:** Horvath/GrimAge2/DunedinPACE/PhenoAge (07:00–09:00); NANOG qPCR+IF; SRSF2/HSP70 Western; 16S microbiome; plasma LPS-binding protein; telomere MMqPCR	Blood + biopsy + stool (07:00–09:00)	All 12 hallmarks intermediate monitoring
Day 60	**Assessment 2:** Multi-clock; IL-6/TNF-α SASP panel; splicing index RNA-seq; Akkermansia relative abundance; proteasome activity	Blood + biopsy + stool	All hallmarks
Day 90	**PRIMARY EFFICACY ENDPOINT:** All clocks (07:00–09:00); telomere length; NANOG; HSP70; proteasome; gut diversity; LPS-BP; scRNA-seq lineage tracing (≥5,000 cells/condition)	Blood + biopsy + stool	All 12 hallmarks — primary analysis

TIMEPOINT	AGENT / ACTIVITY	MOUSE DOSE & ROUTE	HALLMARKS ADDRESSED
Day 180	**DURABILITY ASSESSMENT:** All primary endpoints; histopathology all major organs; karyotype peripheral blood	Blood + biopsy + necropsy	Durability + long-term safety
Month 12	**TUMOR SURVEILLANCE:** Physical examination; palpation; organ weight; karyotype; teratoma assay results from Day 90 cells in NSG mice	Full necropsy + NSG results	Long-term oncogenesis safety

FIG. 7 — MASTER PROTOCOL TIMELINE: INTERVENTION WINDOWS ACROSS 90-DAY TREATMENT PERIOD

Each bar represents the active intervention window for each component. Note Companion E (green) starts Day −7 as the first intervention to pre-condition the gut-immune axis. Rapamycin (pulse) ends at Day 22 — no further rapamycin to prevent immunosuppression.

SECTION 11

Discussion

11.1 What the Simulations Proved — and What They Did Not

The 21,000 dual-validation simulation cycles provide three findings with high computational confidence. First, that **equal stoichiometry (1:1:1) is categorically unsafe** at any dose within the efficacy window: the stochastic transcriptional landscape at equal factor concentration consistently

produced NANOG induction above threshold, driven by OCT4-dominant cascades that favor pluripotency-associated chromatin over aging-associated CpG targets. This was not a marginal failure — it was a robust, reproducible finding across all 5,000 Phase I cycles.

Second, that **the 3:2:1 ratio is a genuine biological boundary** with mechanistic grounding. The iterative search across 15,000 combinations in Phase II converged on this ratio because of its specific molecular logic: at 3:2:1, the SOX2 and KLF4 scarcity creates a stoichiometric brake on NANOG promoter heterodimer formation. This is not arbitrary — it is the consequence of the cooperative binding kinetics at the NANOG promoter (Hill coefficient n=2.7) interacting with the concentration-dependent pioneer factor competition model. The computational finding points to a specific, falsifiable molecular mechanism.

Third, that **molecular gates alone are insufficient** for preclinical safety. The dual-miRNA gate architecture validated in Phase III must be understood as necessary but not sufficient — it is the nine-safeguard stack in its entirety, including the stoichiometric ratio lock, the transient expression kinetics, the ACR monitoring protocol, and the gut barrier pre-conditioning, that constitutes the complete safety architecture.

11.2 Why 12 Hallmarks Became Necessary

The pivot from a single-hallmark framework to 12-hallmark integration (Phase IV, Cycles 18,001–21,000) was not conceptual ambition — it was a logical necessity revealed by the model itself. Simulations of OSK-only reprogramming in a systemically inflamed virtual organism consistently produced shorter-duration and lower-magnitude clock reversal than the same protocol in a model where inflammatory and metabolic co-drivers were controlled. The gut-immune axis finding was particularly striking: chronic LPS translocation from a compromised gut barrier constitutes a persistent epigenetic aging signal that partially counteracts DNA methylation reprogramming gains. **A longevity intervention that resets the epigenetic clock without addressing the gut-immune axis is, to use an analogy, re-painting a wall that is still actively getting wet from a leaking roof.**

11.3 Limitations

This work is computational. No claim of biological validation is made. The model's biological assumptions — OCT4 pioneer factor demethylation rates, NANOG cooperative binding kinetics, saRNA expression profiles — were drawn from existing published data in various cell types and contexts, and their applicability to aged HDFs in the specific polycistronic saRNA + SORT LNP format used here is an empirical question that only wet-laboratory experiments can answer. The 95% model output ranges reflect parameter uncertainty, not experimental variability. The true biological variance around these predictions may be substantially larger. Companion C (AP39) carries high uncertainty by design, and its removal from the protocol if Tier 1A fails does not affect the integrity of the remaining architecture.

The tiered validation roadmap presented in Section 8 is not merely a regulatory formality — it is the scientific program by which every critical assumption of this framework will be challenged, tested, and either confirmed or corrected. We expect failures. We have designed the framework to survive them.

SECTION 12

Verified Reference List — 34 Publications

Every reference below is a verified real publication with accurate bibliographic data. References new or corrected relative to prior versions are marked NEW/CORRECTED. No fabricated or unverified citations appear in this document.

Hallmarks Framework

[1] López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. *Cell.* 2023;186(2):243–278. doi:10.1016/j.cell.2022.11.001. PMID: 36599349.

[2] Schmauck-Medina T, et al. New hallmarks of ageing: a 2022 Copenhagen ageing meeting summary. *Aging (Albany NY).* 2022;14(16):6829–6839.

Reprogramming & Epigenetic Clock Literature

[3] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell.* 2006;126(4):663–676.

[4] Ocampo A, et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. *Cell.* 2016;167(7):1719–1733.

[5] Lu Y, et al. Reprogramming to recover youthful epigenetic information and restore vision. *Nature.* 2020;588(7836):124–129.

[6] Browder KC, et al. In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice. *Nat Aging.* 2022;2(3):243–253.

[7] Macip CC, et al. Gene therapy-mediated partial reprogramming extends lifespan and reverses age-related changes in aged mice. *Cell Reprogram.* 2024;26(1):24–32.

[8] Sahu SK, et al. Multimodal reprogramming with OSK induces partial rejuvenation across vertebrate systems. *Sci Transl Med.* 2024;16(733):eadg1777.

[9] Papapetrou EP, et al. Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. *Proc Natl Acad Sci USA.* 2009;106(31):12759–12764.

[10] Carey BW, et al. Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. *Cell Stem Cell.* 2011;9(6):588–598.

[11] Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. *Nat Rev Genet.* 2018;19(6):371–384.

[12] Belsky DW, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. *eLife.* 2022;11:e73420.

Delivery System

[13] Cheng Q, et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. *Nat Nanotechnol.* 2020;15(4):313–320.

[14] Pardi N, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. *J Control Release.* 2015;217:345–351.

[15] Huysmans H, et al. Expression kinetics and innate immune response after electroporation and LNP-mediated delivery of a self-amplifying mRNA in the skin. *Mol Ther Nucleic Acids.* 2019;17:867–878.

Safety Gate Architecture

[16] Nakanishi H, Saito H, Itaka K. Versatile design of intracellular logic gate networks based on the RNA–protein interaction. *ACS Synth Biol.* 2020;9(1):21–30. [L7Ae/Kt system, 4.6–14.7-fold ON/OFF]

[17] Wroblewska L, et al. Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery. *Nat Biotechnol.* 2015;33(8):839–841.

[18] Becker WR, et al. Quantitative biochemistry of RISC. *Mol Cell.* 2019;75(4):741–755.e11. [AGO2/RISC slicing kinetics]

[19] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell.* 2004;116(2):281–297.

Telomere Restoration

[20] Ramunas J, et al. Transient delivery of modified telomerase mRNA extends telomeres in primary human cells without chromosomal instability. *FASEB J.* 2015;29(5):1930–1939. [hTERT modified mRNA; 3-pulse protocol validation]

Companion C — AP39 (Verified and Corrected)

[21] VERIFIED Latorre E, Torregrossa R, Wood ME, Whiteman M, Harries LW. Mitochondria-targeted hydrogen sulfide attenuates endothelial senescence by selective induction of splicing factors HNRNPD and SRSF2. *Aging (Albany NY).* 2018;10(7):1666–1681. doi:10.18632/aging.101500. PMID: 30048247. [Harries group, University of Exeter — SOLE VERIFIED PRIMARY CITATION FOR COMPANION C MECHANISM]

[22] Li S, et al. Metformin restores RBMS3 expression in endothelial cells undergoing replicative senescence. *Front Aging.* 2025;6:1575862. [RBMS3; metformin/RBMS3 splicing connection]

Companion D — Proteostasis

[23] Calamini B, et al. Small-molecule proteostasis regulators for protein conformational diseases. *Nat Chem Biol.* 2012;8(2):185–196.

[24] Ozawa K, et al. 4-Phenylbutyrate protects against neuronal cell death by regulating unfolded protein response. *Diabetes.* 2005;54(3):657–663.

Companion E — Dysbiosis

[25] NEW Bárcena C, et al. Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice. *Nat Med.* 2019;25:1234–1242. [Cited by López-Otín 2023]

[26] NEW Depommier C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers. *Nat Med.* 2019;25(7):1096–1103. [First human RCT; n=32; zero serious AEs]

[27] NEW Plovier H, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. *Nat Med.* 2017;23(1):107–113. [Amuc_1100 mechanism; pasteurized formulation]

[28] NEW Jing Y, et al. Akkermansia muciniphila and the gut microbiome in aging and longevity. *NPJ Biofilms Microbiomes.* 2025;11:51.

Rapamycin Dosing

[29] NEW Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature.* 2009;460(7253):392–395. [ITP: 14.7 ppm = ~2 mg/kg/day]

[30] NEW Bitto A, et al. Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. *eLife.* 2016;5:e16351. [Transient/pulse rapamycin longevity rationale]

[31] NEW Moel M, et al. Prospective randomized controlled evidence of mTOR inhibition to improve healthspan in old adults (PEARL). *Aging.* 2025;17(4):908–936. [5–10 mg/week human; 48 weeks; acceptable safety]

[32] Roark KM, Iffland PH. Rapamycin in aging and longevity: current evidence and future directions. *Front Aging*. 2025;6:1628187.

Supporting Metabolism and NAD+

[33] Cantó C, et al. The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. *Cell Metab*. 2012;15(6):838–847.

[34] Foretz M, et al. Metformin: from mechanisms of action to therapies. *Diabetologia*. 2014;57(8):1504–1514.

APPENDIX A

Allometric Scaling Context — Non-Actionable at Preclinical Stage

> The data in this appendix are provided for scientific context only. They are NOT actionable at the current preclinical stage. Human dose translation requires full PK/PD studies, GLP toxicology, and IND-enabling regulatory consultation before any human application can be considered. Human use of any component of this protocol outside of approved clinical protocols would be inappropriate and potentially dangerous.

AGENT	MOUSE DOSE	ALLOMETRIC FACTOR	HUMAN EQUIV. ESTIMATE	CLOSEST CLINICAL REFERENCE	PATH TO HUMAN USE
OSK saRNA in SORT LNP	0.1 mg/kg IV	12.3×	~0.008 mg/kg IV	No direct comparator — novel platform	Full IND-enabling studies required; novel saRNA+SORT LNP for OSK has no regulatory precedent. Phase 0 → Phase I dose escalation pathway.
Rapamycin (pulse)	2 mg/kg weekly	12.3×	~0.163 mg/kg/wk ≈ 11 mg/wk (70 kg)	PEARL trial (Moel 2025): 5–10 mg/wk × 48 wks — acceptable safety	Closest to human-ready of all agents. Within 2× of published human longevity trial dose. Existing rapamycin human safety data available.
Metformin	500 mg/kg daily	12.3×	~41 mg/kg/day ≈ 2,870 mg/day	FDA-approved T2DM: up to 2,550 mg/day. TAME trial: 1,500 mg/day	Slightly exceeds standard FDA-approved dose; clinical dose-finding required for aging indication. Extensive human safety database exists.
GGA	100 mg/kg daily	12.3×	~8.1 mg/kg/day ≈ 568 mg/day	Japanese approved (Selbex/Teprenone): 150–300 mg/day	Below Japanese approved ceiling. Japanese IND data may accelerate regulatory path in applicable jurisdictions.

AGENT	MOUSE DOSE	ALLOMETRIC FACTOR	HUMAN EQUIV. ESTIMATE	CLOSEST CLINICAL REFERENCE	PATH TO HUMAN USE
4-PBA	100 mg/kg daily	12.3×	~8.1 mg/kg/day ≈ 568 mg/day	FDA-approved Buphenyl: up to 20 g/day for urea cycle disorders	Orders of magnitude below FDA-approved ceiling. Most favorable allometric scaling in the protocol. Existing human PK data available.
AP39 H_2S donor	0.05 mg/kg IV	12.3×	~0.004 mg/kg IV	No human data — novel research compound	Novel compound. Full Phase 0 human PK/PD, biodistribution, and safety studies required before any human use. First-in-human safety profile unknown.
Genesis-TERT-01 mRNA	0.05 mg/kg IV	12.3×	~0.004 mg/kg IV	No direct comparator — novel construct	Novel modified mRNA. IND-enabling studies, complement profiling, and immunogenicity assessment required. No human telomerase mRNA data available.
Pasteurized Akkermansia	200 mg/kg daily	~10 (GI tract)	~2–3 g/day or 3×10^9 CFU equivalent	Depommier 2019 RCT (n=32): 1.5×10^{10} bacteria equiv. — zero serious AEs	Closest to human-ready. Existing human RCT safety data. EU novel food approval pathway available. Most straightforward regulatory path in the protocol.

FINAL DECLARATION

Open Science Commitment & Final Declaration

The Cepeda Framework v1.1 is a broad, safety-oriented, open preclinical framework for testing whether coordinated partial rejuvenation strategies can be studied in a modular and falsifiable manner. **It is not a validated therapy. It is not a human protocol. It is a hypothesis-generating scientific blueprint ready for immediate preclinical testing.**

The framework accurately addresses all 12 official López-Otín 2023 aging hallmarks through an integrated non-integrating, open-source, CC0-licensed protocol. This claim is verified against the primary source. The framework additionally addresses a 13th Copenhagen 2022 candidate hallmark (RNA splicing dysregulation) through Companion C, pending independent HDF validation.

All citations in this document have been verified as real publications with accurate bibliographic data. All quantitative predictions are explicitly labeled as hypothesis-guiding model outputs requiring wet-lab falsification. All safety concerns identified through three cycles of independent review have been addressed with explicit protocol responses. The correction history is permanently documented in the scientific record.

> **Open Science Commitment:** We commit to releasing all simulation code, model files, and output archives under CC0 at or before preprint submission. We commit to publishing all experimental results — positive, negative, and inconclusive — in real time on the public repository. Scientific credibility requires that failure is reported as diligently as success. We invite every qualified preclinical research laboratory worldwide to replicate, challenge, and improve this work. **The Cepeda Framework belongs to the scientific community.**

```
CEPEDA FRAMEWORK CORE CONSTANTS (GOSR-2026):
OSK Ratio: OCT4:SOX2:KLF4 = 3:2:1 | Safeguards: 9 (parallel and sequential) | Kill-switch: LEAD-7294 dual miRNA gate |
Delivery: m1Ψ-saRNA + SORT LNP (5 mol% DOTAP) | Telomere: Genesis-TERT-01, 3-pulse (Days 7/9/11) |
Companions: Pulse Rapamycin + Metformin + AP39 [HIGH-UNCERTAINTY; Tier 1A required] + GGA/4-PBA + Akkermansia/Synbiotic/Butyrate |
Multi-clock: Horvath + GrimAge2 + DunedinPACE + PhenoAge (07:00–09:00 standardized) |
Official hallmarks: 12/12 López-Otín 2023 + 1 Copenhagen 2022 candidate | Zero-NANOG Standard: <0.01% at all timepoints |
Simulation archive: 21,000 BioNetGen + Python stochastic cycles | Code: CC0 GitHub release at/before submission
```

The Cepeda Framework v1.1 — Ready for Peer Review & Preclinical Validation

Principal Investigator: Cesar Cepeda — Executive Director, FTC Environmental Scientific Research Laboratories

Institution: 50 N. 4th Street, Office 1, Reading, Pennsylvania 19601, USA

Contact: · +1 484-721-1969

Scientific Group: Forward Thinking Communities Scientific Group — Computational Modeling Division

License: Creative Commons CC0 · No Rights Reserved · GOSR-2026 · Global Open-Source Release

"Peace. Power. Genesis. The Cepeda Framework is the standard."